Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn

Executive Summary

Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma

You may also be interested in...



Investors Balk At AMAG-Allos Proposed Marriage

An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.

Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies

FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.

Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies

FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.

Related Content

Topics

UsernamePublicRestriction

Register

PS051526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel